Century Therapeutics
Century Therapeutics is a clinical-stage biotechnology company that develops allogeneic, iPSC-derived cell therapies — including CNTY-813 for Type 1 Diabetes and CNTY-101, CNTY-308, and CARAMEL for B-cell-mediated autoimmune diseases and oncology — and is funded through its Bristol-Myers Squibb collaboration and equity financings.
- Company typePublic
- Founded2018
- HeadquartersPhiladelphia, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Century Therapeutics does
Century Therapeutics is a Philadelphia-based, NASDAQ-listed (IPSC) clinical-stage biotechnology company founded in 2018 that develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases — including Type 1 Diabetes and B-cell-mediated autoimmune diseases — and hematologic and solid tumor cancers. The proprietary platform integrates CRISPR-MAD7 gene editing for precise knock-in and knock-out without random integration, common engineered iPSC progenitor cells, a Cell Foundry differentiation process, and Allo-Evasion™ immune evasion technology (versions 1.0 and 5.0) intended to avoid host immune rejection and enable repeat dosing without intensive preconditioning. The product portfolio comprises CNTY-813 (iPSC-derived beta islet cells for Type 1 Diabetes, IND targeted for Q4 2026), CNTY-308 (CD19-targeted CAR-iT cells for B-cell-mediated autoimmune diseases, entering clinical trials in 2026), CNTY-101 (CAR-iNK cells for B-cell-mediated autoimmune diseases in an investigator-sponsored trial at Friedrich-Alexander University Erlangen-Nürnberg), and the platform itself; a manufacturing sublicense and technology base developed from prior acquisitions of Empirica Therapeutics (2020) and Clade Therapeutics (April 2024).
The business model is pre-commercial products with revenue generated entirely through a strategic collaboration with Bristol-Myers Squibb, which produced $109.2M of collaboration revenue in Q1 2025 versus $6.6M in the prior-year period and zero collaboration revenue in Q1 2026. Distribution occurs through company-sponsored and investigator-sponsored clinical trials at research hospitals and specialty centers, with future commercialization expected to target hospitals and specialty clinics serving oncology and autoimmune disease patients. Operations are funded by equity: a $250M Series B (2019), $160M Series C (2021), $150M strategic investment from Bristol-Myers Squibb (2022), a $60M private placement (April 2024), and a $135M oversubscribed private placement in January 2026 that, together with a $150M ATM program and $217M cash and equivalents at March 31, 2026, funds operations into Q1 2029. Century employed 101-250 staff as of the most recent disclosure and reported a $21.6M net loss for Q1 2026.
Century Therapeutics firmographics
Firmographics- Name
- Century Therapeutics
- Legal name
- Century Therapeutics, Inc.
- Website
- https://centurytx.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Century Therapeutics is a clinical-stage biotechnology company that develops allogeneic, iPSC-derived cell therapies — including CNTY-813 for Type 1 Diabetes and CNTY-101, CNTY-308, and CARAMEL for B-cell-mediated autoimmune diseases and oncology — and is funded through its Bristol-Myers Squibb collaboration and equity financings.
- Ownership category
- akta.pro rank
Century Therapeutics industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)
Keywords
Where Century Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Century Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Collaboration Revenue: Revenue from strategic collaborations with pharmaceutical partners, including collaboration agreements for development activities. Historical collaboration revenue of $109.2 million from Bristol-Myers Squibb in Q1 2025, compared to $6.6 million in the prior year period. No collaboration revenue in Q1 2026.
- Future Product Revenue: Pre-revenue clinical stage company. No commercialized products. Future revenue will come from potential FDA-approved cell therapy products for autoimmune diseases and cancer upon successful completion of clinical trials and regulatory approval.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Century Therapeutics product offering
Product offeringCore offering
Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases (including Type 1 Diabetes) and cancer. Its pipeline candidates (CNTY-813, CNTY-308, CNTY-101, CARAMEL IST) are engineered with proprietary Allo-Evasion™ immune evasion technology and CRISPR-MAD7 gene editing to enable off-the-shelf, redosable therapies manufactured from a single iPSC clone master cell bank. The company is pre-revenue, generates collaboration revenue (notably from Bristol-Myers Squibb), and targets commercial distribution through hospitals and specialty clinics upon regulatory approval.
Product overview
Century Therapeutics is a biotechnology company developing an industry-leading allogeneic, iPSC-derived cell therapy platform for autoimmune diseases (including Type 1 Diabetes) and cancer. The company's product portfolio consists of multiple clinical and preclinical candidates: CNTY-813 (iPSC-derived beta islet cells for Type 1 Diabetes), CNTY-308 (CD19-targeted CAR-iT cells for B-cell-mediated autoimmune diseases), CNTY-101 (CAR-iNK cells for B-cell-mediated autoimmune diseases), and CARAMEL IST (iT cells for autoimmune diseases and solid tumors). All product candidates incorporate the proprietary Allo-Evasion™ immune evasion technology. The platform is built on iPSC cell foundry capabilities that leverage CRISPR-MAD7 gene editing, CAR and protein engineering, and common engineered iPSC progenitors to generate a consistent, scalable manufacturing process.
Differentiator
Problem solved
Functional benefit
Products and services
- CNTY-813 iPSC-derived beta islet cell therapy engineered with Allo-Evasion™ 5.0 technology, designed to protect from T cell, NK cell, and humoral immune rejection for durable glycemic control without systemic immunosuppression. Being developed as a potential functional cure for Type 1 Diabetes.
- CNTY-308 CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, functionally comparable to primary T cells. Being developed as a potential treatment for B-cell-mediated autoimmune diseases.
- CNTY-101 CAR-iNK cell therapy with six precision gene edits, incorporating Allo-Evasion™ 1.0 technology. Being developed as a potential treatment for patients with B-cell-mediated autoimmune diseases.
- CARAMEL IST iT cell therapy engineered with Allo-Evasion™ 5.0, being developed for B-cell-mediated autoimmune diseases, solid tumors, and other indications under an investigator-sponsored trial by researchers at Friedrich-Alexander University Erlangen-Nürnberg.
Quantifiable outcome
- CNTY-813 demonstrated sustained glucose control for more than eight months in preclinical mouse models without chronic immunosuppression
- +3 more outcomes
Companies that use Century Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
Century Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Century Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and core.
- Bristol-Myers SquibbmajorStrategic collaboration with Bristol-Myers Squibb for cell therapy development. Collaboration revenue was $109.2 million in Q1 2025 compared to $6.6 million in prior year period, reflecting milestone payments and development activities under the partnership agreement.
- Clade TherapeuticsmajorAcquired by Century Therapeutics in April 2024 to enhance pipeline and platform capabilities. Clade Therapeutics was a privately-held cell therapy company focused on iPSC-derived αβ T cell programs and technology spanning cancer and autoimmune diseases, founded by Chad Cowan.
- Friedrich-Alexander University Erlangen-NürnbergcoreInvestigator-sponsored trial (IST) for CNTY-101 being conducted by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg for B-cell-driven autoimmune diseases.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Century Therapeutics competitors and assessment
Company assessmentDirect peers
- Fate Therapeutics: Fate Therapeutics is the closest direct peer — also developing iPSC-derived off-the-shelf NK and T-cell therapies (iPSC platform with engineered CD16, CAR, TCR, and antigen receptor constructs). Competes head-to-head in allogeneic, off-the-shelf cell therapy with similar target indications in oncology and increasingly autoimmune disease.
- Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with multiple clinical-stage candidates targeting hematologic malignancies. Direct competitor in the allogeneic cell therapy space with similar manufacturing scale-up ambitions and a broader clinical pipeline than Century.
- Atara Biotherapeutics: Atara develops allogeneic T-cell immunotherapies, including EBV-specific T cells and CAR-T programs. Directly comparable as an allogeneic, off-the-shelf cell therapy developer with overlapping autoimmune and oncology indications.
- Cellectis: Cellectis is a clinical-stage gene-edited allogeneic CAR-T developer using TALEN-based gene editing. Comparable as an allogeneic platform company targeting hematologic malignancies with similar enabling technology (gene editing + allogeneic cell therapy).
- Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR-based gene editing (similar enabling technology to Century's CRISPR-MAD7). Direct peer in the allogeneic CAR-T space with clinical-stage assets.
- Precision BioSciences: Precision BioSciences develops allogeneic CAR-T therapies using its proprietary ARCUS gene editing platform. Comparable as a gene-editing-enabled allogeneic cell therapy company with oncology and emerging autoimmune indications.
- Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell therapies (SPEAR T-cells) for solid tumors and is expanding into autoimmune indications. Comparable as a cell therapy developer with platform-level manufacturing capabilities and overlapping therapeutic focus areas.
Emerging players
- Sana Biotechnology: Sana is developing hypoimmune-modified iPSC-derived cell therapies to evade immune rejection — a directly comparable technological approach to Century's Allo-Evasion™. Founded by Chad Cowan (Century's CSO) before he moved to Century, creating a direct scientific lineage connection.
- CRISPR Therapeutics: CRISPR Therapeutics is a leading gene editing company co-founded by Chad Cowan (Century's CSO) that is also developing gene-edited cell therapies (including Casgevy, the first approved CRISPR-based therapy). Relevant peer given shared scientific lineage, gene editing platform overlap, and cell therapy ambitions.
Broad incumbents
- Vertex Pharmaceuticals: Vertex is advancing zimislecel (acquired via ViaCyte), a stem cell-derived islet cell therapy for Type 1 Diabetes, putting it in direct competition with Century's CNTY-813 lead program. Far larger and more resourced incumbent in the T1D cell therapy space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Century Therapeutics social profiles
Digital presenceCentury Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Century Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Century Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Century Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors26 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Century Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Century Therapeutics
What does Century Therapeutics do?
Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases (including Type 1 Diabetes) and cancer. Its pipeline candidates (CNTY-813, CNTY-308, CNTY-101, CARAMEL IST) are engineered with proprietary Allo-Evasion™ immune evasion technology and CRISPR-MAD7 gene editing to enable off-the-shelf, redosable therapies manufactured from a single iPSC clone master cell bank. The company is pre-revenue, generates collaboration revenue (notably from Bristol-Myers Squibb), and targets commercial distribution through hospitals and specialty clinics upon regulatory approval.
Is Century Therapeutics a public or private company?
Century Therapeutics is a public company. It is classified as public and is currently operating.
When was Century Therapeutics founded?
Century Therapeutics was founded in 2018. It employs 101 to 250 people.
Where is Century Therapeutics based?
Century Therapeutics is headquartered in Philadelphia, United States, in the North America region.
How does Century Therapeutics make money?
Two revenue lines are on record. Collaboration Revenue is the primary driver. The others are future Product Revenue.
Who are Century Therapeutics's main competitors?
Direct peers on record are Fate Therapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellectis, Caribou Biosciences, Precision BioSciences and Adaptimmune Therapeutics. Emerging players are Sana Biotechnology and CRISPR Therapeutics. Vertex Pharmaceuticals is listed as a broad incumbent.
Does Century Therapeutics have an API?
No public API is recorded for Century Therapeutics.
What industry is Century Therapeutics in?
Century Therapeutics's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.